PhagePro

Executive Summary

PhagePro is a Boston-based biotechnology company dedicated to advancing phage therapy as a solution for antibiotic-resistant bacterial infections. Founded in 2016, the company brings together a team of phage and bacteria experts, collaborating with public policy makers, industry leaders, and community stakeholders to drive innovation in underserved populations. Although the company's pipeline details remain undisclosed, PhagePro is positioned to address the growing global threat of antimicrobial resistance by developing targeted bacteriophage-based therapeutics. Given its focus on collaborative innovation and public-private partnerships, the company aims to bridge the gap between preclinical research and clinical deployment, potentially offering a novel alternative to conventional antibiotics.

Upcoming Catalysts (preview)

• Q4 2026Partnership announcement with a major healthcare or academic institution40% success
• TBDIND filing for lead phage candidate30% success
• Q3 2026Grant award from federal or philanthropic antimicrobial resistance initiative50% success